What is Altach?
Altach, founded in 2022 and emerging from pioneering research at Trinity, is developing a novel biomimetic scaffold derived from Type II collagen. This innovative material holds significant promise for applications requiring advanced biological scaffolding, positioning Altach at the forefront of biomaterials innovation.
How much funding has Altach raised?
Altach has raised a total of $1.3M across 1 funding round:
Other Financing Round
$1.3M
Other Financing Round (2024): $1.3M with participation from NLC Health Center
Key Investors in Altach
NLC Health Center
NLC Health Center, operating within the Hospitals & Physicians Clinics industry, likely provides strategic insights and potential clinical validation for Altach's biomimetic scaffold technology.
What's next for Altach?
With this substantial enterprise-level funding, Altach is poised for accelerated growth and product commercialization. The strategic investment suggests a focus on scaling operations, expanding research and development capabilities, and potentially forging key partnerships to bring its unique biomimetic scaffold technology to market. This capital injection will likely enable Altach to navigate its next phase of development, moving from a research-intensive startup to a more established player in the advanced materials or biotechnology sector.
See full Altach company page
